April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

Macular Thickness as a Noninvasive Biomarker for Postoperative Delirium

Interocular asymmetry in retinal structure is common and may be influenced by hemispheric differences in neurodegeneration.

Conexiant

April 02, 2025

Unequal Access Worsens Opioid Crisis for Black Patients

Despite rising opioid overdose rates among Black patients, systemic barriers and unequal access to treatment continue to hinder recovery efforts and worsen outcomes.

KFF Health News

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 24, 2025

High Treatment-Resistant Depression Rates in Real-World Depression Cohort

Researchers found that nearly half of patients with major depressive disorder met criteria for treatment-resistant depression.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

February 07, 2025

Long-Term Rise in Cannabis-Associated Schizophrenia Cases, Predating Legalization

Researchers found that the proportion of schizophrenia cases linked to cannabis use disorder nearly tripled post-legalization, with the highest impact among young males.

Conexiant

March 04, 2025

Esketamine Efficacy Questioned 6 Years Following Approval

Analysis reveals "less is more" approach may be prudent for ketamine-derived depression treatment

Conexiant